Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Launching Photonic Encryption for Data Security in the Post-Quantum Era with the CyberRidge All-Optical Stealth and Secured Solution for High-Speed Coherent Optical Communication (CyberRidge - Carmel)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Quantum computing offers humanity a great number of potential benefits but also poses unprecedented cybersecurity threats, creating data breaches to vital systems such as health and finance. While this might not be an imminent problem, these developments create a ""harvest now, decrypt later" problem where hackers are storing encrypted data now, anticipating the ability to crack it later. Our Carmel device is the only “record-proof encryption” solution in the world. No data, nothing to hack. We use photonic deconstruction™ to transform data into undecipherable optical noise and photonic reconstruction™ to transform optical noise into its original digital data. All optical processing using ultra-short pulses has great promise for telecommunication. It enables power saving, virtually zero latency, high bandwidth, and minimal electromagnetic signature. As quantum computing is expected to reach its milestone in 2030, now is the right time for a paradigm change from mathematics to photonics solutions like CyberRidge, as we provide the only commercially photonic encryption solution to protect data from cybersecurity attacks for post-quantum computing. CyberRidge Ltd. was established in December 2021 in Israel with our R&D center in Tel Aviv by our Co-Founders, Prof. Dan Sadot and Dr. Eyal Wohlgemuth. We follow a direct pricing model of the equipment hardware including charging a reasonable premium for our unique security functionality. The CyberRidge Pizza box (“Carmel”) price will be in the €72.6k-€90.7k ($80k-$100k) price range. This allows CyberRidge to create a new market we call photonic encryption. In size, this can be compared to optical encryption plus quantum cryptography, forecasted to reach €9 billion. Our multidisciplinary, highly experienced team consists of 14 (5 in leadership) people with 4 of our team members being women (29% women and 71% men). CyberRidge responds to the EIC Accelerator Challenge “Emerging semiconductor and Quantum technology components".

Keywords: photonic encryption,post quantum cybersecurity,harvest resistant encryption,photonic deconstruction,photonic reconstruction,photonic key,physical layer security,quantum cryptography
Precision Diagnostic Platform for prognostic risk-profiling of disease progression and prediction of treatment response of cancer patients (Stratipath PDP)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Sweden
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 36.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Stratipath, a pioneer in AI-based precision oncology, has developed a groundbreaking diagnostic platform based on over a decade of research. This platform offers prognostic risk profiling of disease progression and treatment response prediction, setting new industry standards for enhanced treatment decisions and improved patient outcomes. Cancer affects one in two individuals, posing significant challenges to healthcare systems. Current diagnostics often yield inconclusive results, come with exorbitant costs, and are very time-consuming. Tailoring treatment for each patient is vital, yet nearly 95% of EU cancer patients lack access to prognostic and predictive diagnostics due to these limitations. Stratipath leverages AI to analyse routine histopathological images (biopsies and resected tumours) for prognosis and treatment response predictions, surpassing human capabilities and offering a cost-effective alternative to molecular assays, delivering results in minutes instead of weeks. This capability is primarily attributed to our exclusive, proprietary longitudinal data, encompassing histopathological images and comprehensive clinical and patient outcomes data. The platform ensures scalability and seamless integration with existing workflows. The EIC grant will co-finance the finalization of our breast cancer solution. Project objectives include: (i) Finalizing the development of first-in-class breast cancer solutions; (ii) Further upgrading the platform; (iii) Conducting validation studies, obtaining regulatory approvals and inclusion in national treatment guidelines; (iv) Securing intellectual property rights and conducting communication and dissemination activities. This project represents a pivotal shift in prognostic risk profiling and treatment response prediction, providing a scalable alternative to costly, time-consuming molecular assays. It promises significant benefits for both healthcare systems and individual patients, ushering in a new era of cancer care

Keywords: ai oncology pathology precision medicine diagnostics breast prognostic predictive
Revolutionary high-efficient, low-cost and recyclable Al-ion batteries for stationary energy storage applications. (ABSA)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Spain
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Traditional batteries, such as lead-acid, nickel-cadmium (Ni-Cd), and lithium-ion (Li-ion), are burdened by several significant issues. These include high production costs, safety risks due to flammable electrolytes and toxic materials, inefficiencies with energy losses, and a limited lifecycle. Additionally, these technologies struggle with temperature sensitivity, requiring complex cooling systems to operate effectively, and pose serious environmental and health hazards due to their toxic components. The growing demand for reliable and sustainable energy storage highlights an unaddressed need in the market. Europe’s reliance on Asia for battery materials and technology further exacerbates this issue, with rising costs and environmental concerns making it imperative to find alternative solutions. Traditional batteries have managed to achieve a maximum efficiency of only 65-90%, and their limited lifecycle requires frequent replacements, increasing costs and environmental impact. Zelestium's aluminium-ion (Al-ion) battery technology directly addresses these challenges, offering a high-efficiency, cost-effective, and environmentally friendly solution. By using sustainable materials such as aluminium, carbon, and urea, Zelestium eliminates the need for hazardous substances, ensuring safety and recyclability. Their innovative multilayer electrode-dielectric-electrode structure prevents common issues like short circuits and hot spots, enabling the batteries to operate efficiently at temperatures above 55°C and achieve a cycle life of 6,000 cycles—far exceeding the performance of existing battery technologies. In the planned EIC project, Zelestium will focus on the prototype testing and validation of its ABSA batteries. By producing and testing 10,000 cells, the project aims to establish a new benchmark in battery technology, significantly reducing Europe’s dependency on imports and positioning Zelestium as a leader in the global market.

Keywords: aluminium ion batteries,energy storage,sustainability,circular economy,production technology,process engineering
Development of CycloRotors as aviation propulsion system for electric VTOL with unique maneuverability and compact design capability, enabling new market segments in urban air mobility (CycloRotor)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Austria
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 36.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

CycloTech is an aviation propulsion technology company developing the CycloRotor, a revolutionary electric propulsion system ideally suited for electric vertical take-off and landing (eVTOL) applications. The key advantage of our technology is its unique ability to instantly control the magnitude and direction of thrust 360° around the axis of rotation, when other systems like rotors or jet engines can generate thrust only in one direction. CycloRotor provides easy transition from hover to forward flight, superior manoeuvrability, especially in harsh weather conditions, and the ability to decouple flight path from vehicle attitude. By combining lift and thrust generation in one unit, vehicles equipped with CycloRotor can be much smaller than those with conventional propulsion systems. Urban Air Mobility aims to solve major transportation problems such as high emissions, congestion in urban transport and high infrastructure costs for road, rail or underground. AirTaxis are the first step in this emerging industry, but eventually urban air vehicles to replace the car as an individual mobility solution. Our CycloRotor will be the key enabler for small size and low cost eVTOLs to be affordable to the masses. New eVTOL companies as well as established automotive players in Europe can integrate this propulsion technology into their future design, securing Europe's leadership in urban air mobility and creating a multi-layer ecosystem. Up to now, we have invested 28 MEUR to reach TRL 6. As aeronautics has long development cycles comparable to pharmaceuticals, we need the EIC as patient money to match the 20 MEUR committed by our investors to bring the technology to TRL 9.

Keywords: aviation,propulsion system,e mobility,urban air mobility,cyclogyro,evtol,airtaxi,transportation,aerospace,voith schneider propeller,decarbonization,autonomous flying
Alternative routes for basic chemicals production using hydrogen as feedstock (ALCHEMHY)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Industry
Destination: Climate neutral, Circular and Digitised Production
Action type: Research and Innovation actions
Partnership: Processes4Planet (co-programmed)
Countries involved: Spain,Slovenia,Portugal,Italy,Belgium,Greece,Austria,Switzerland
Call: Renewable hydrogen used as feedstock in innovative production routes (Processes4Planet Partnership) (RIA) (HORIZON-CL4-2024-TWIN-TRANSITION-01, 2024)
Start date: 2024-10-01
End date: 2028-09-30
Duration (months): 48.0
Total project cost (EUR): 9996078.75
EU funding (EUR): 9996078.75
Participants: 16
Project status: SIGNED

ALCHEMHY aims to develop a set of innovative electrified processes to produce platform chemicals, particularly ammonia, i.e. a Magnetic-Heated Sorption-Enhanced Reactor (MSER) and Direct ElectroSynthesis of Ammonia (DESA); and methanol, i.e. a Small-Flexible Methanol Reactor (SFMR) and a Plasma-Catalytic Hydrogenation process (PCH). To this end, processes configuration will be optimised and novel materials and catalysts comaptible with the electric input will be developed, optimising their performance, ramp-up times and enabling milder conditions. This will support the intensification and downscaling of the ammonia and methanol production, facilitating decentralised production integrated with downstream processes and renewable energy generation. This is crucial to decarbonise the production of both chemicals, as current production heavily relies on fossil natural gas for hydrogen generation. The 4 processes will be demonstrated at TRL 6 in relevant experimental facilities, while the technical and economic feasibility of the processes will be studied through a technoeconomic assessment (TEA) in two use cases: integrated ammonia and caprolactam production and refinery decarbonisation through CCU + a downstream methanol-to-olefin process. The processes upscaling, operation and TEA will be supported through dynamic modelling of the processes, generating a digital twin of the processes and a DSS to support H2 value chain design. The project consortium consists of 16 partners from 7 EU countries, with diversified expertise and knowledge in the addressed processes and access to the required lab and pilot infrastructure. The project will contribute to the development of a sustainable chemical industry, supporting the creation of green jobs and improving the competitiveness of European industries, while contributing to a more resilient and secure energy system for the EU, reducing its dependence on imported fossil fuels.

Keywords: hydrogen,ammonia,methanol,electrification,process intensification,decentralisation,digital twin,process modelling,process integration,thermo catalysis,induction,plasma,electrosynthesis
Disrupting the myofibroblast cell cycle to treat Kidney Fibrosis with a novel small molecule compound inhibitor (DISRUPT-KF) (DISRUPT-KF)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Germany
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2024-POC, 2024)
Start date: 2025-06-01
End date: 2026-11-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: SIGNED

Chronic kidney disease (CKD) is a progressive disease in which kidney function is gradually lost. It can develop consequent of many (kidney) diseases and it affects more than 10% of the world population. Although in recent years sodium–glucose cotransporter 2 inhibitors and novel non-steroidal mineralocorticoid antagonists are showing significant effects on CKD, the majority of patients treated still progress towards end-stage renal disease (ESRD). With dialysis or kidney transplantation as the sole treatments available in case of ESRD, the disease represents an enormous burden on healthcare costs throughout Europe. Caused by organ injury, fibrosis leads to replacement of functional tissue and organ architecture by extracellular matrix, leading to tissue scar formation and impaired function of the affected organ. This makes fibrosis a key therapeutic target to improve organ function in e.g., CKD. Myofibroblasts are the key driver cells of fibrosis across organs and research in our lab has demonstrated that targeting myofibroblasts stabilises organ function. Additionally, we have identified GLI1/2 as a myofibroblast cell-cycle progression-specific target. We found that the number of Gli proteins, transcriptional effectors of the Hedgehog signalling pathway, are significantly increased in the kidney after injury. Furthermore, GLI1/2 are ideal targets as they are not expressed during homeostasis in adults. DISRUPT-KF will validate a set of novel Gli inhibitors as disease-modifying drug candidates for CKD. Preliminary evidence shows anti-fibrotic efficacy in human 2D culture platforms and in induced pluripotent stem cell-derived kidney organoids in vitro. During DISRUPT-KF we will further verify and optimise the anti-fibrotic drug candidates in relevant in vitro (kidney fibrosis organoids) and in vivo (mice) models to validate their potential. We will also develop and execute an IP strategy and a commercial feasibility analysis to enter the anti-fibrotic CKD market.
Mitochondrial Precursor Proteins in the Cytosol as Major Determinants of Cellular Health (MitoCyto)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Molecules of Life: B iological  Mechanisms , Structures  and Functions
Panel description: For all organisms : Molecular biology , biochemistry, structural biology, molecular biophysics , synthetic and chemical biology, drug design, innovative methods and modelling
Countries involved: Germany
Call: ERC ADVANCED GRANTS (ERC-2021-ADG, 2021)
Start date: 2022-10-01
End date: 2027-09-30
Duration (months): 60.0
Total project cost (EUR): 2334450.0
EU funding (EUR): 2334450.0
Participants: 1
Project status: SIGNED

Mitochondria are made of 800 to 1500 proteins which represent up to 30% of the cellular mass. Owing to their post-translational mode of import, mitochondrial precursor proteins explore the cytosol before they are imported into mitochondria. These reactions are of utmost importance for cellular functionality since cytosolic precursors pose a major threat of cellular proteostasis and are major drivers in aging and for the pathogenesis of neurodegenerative diseases. Still, the biology of cytosolic precursors is largely elusive. In vitro import assays governed the experimentation platform of the mitochondrial community which enabled exquisite breakthroughs in understanding translocation, but are unsuited to elucidate cytosolic reactions. MitoCyto aims to break out of these experimental walls to elucidate the biology of cytosolic precursors with an interdisciplinary research team that leaves the comfort zone of biochemistry to utilize genetic and cell biology approaches but also develops novel cutting-edge techniques from high throughput approaches, through microfluidics-assisted microscopy to synthetic biology. From this innovative combination, detailed mechanistic insights into three so far largely elusive aspects of cell biology will be possible for the first time: (1) What are the cytosolic interactors of mitochondrial precursor proteins? (2) What are the direct and indirect physiological consequences of cytosolic precursor accumulation? (3) How does the re-routing of mitochondrial proteins to the nucleus control growth and fitness of eukaryotic cells? We are convinced that MitoCyto will break grounds to a comprehensive understanding of how eukaryotic cells maintain a healthy proteome over a lifetime despite fluctuating metabolic conditions. While these goals are conceptually deeply rooted in a comprehensive understanding of basic biological questions, they are of immediate relevance for cancer cell metabolism, neurodegeneration and aging.

Keywords: mitochondria proteostasis aging
Hop On to Baxerna 2.0 (BAXERNA 2.0-HOP ON)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Research and Innovation actions
Countries involved: Belgium,Malta
Call: Hop on Facility (HORIZON-WIDERA-2023-ACCESS-06, 2023)
Duration (months): 30.0
Total project cost (EUR): 599751.25
EU funding (EUR): 599751.25
Participants: 2
Project status: SIGNED

The growing global issue of antimicrobial resistance requires innovative approaches to vaccine R&D, particularly for pervasive intracellular pathogens such as Mycobacterium tuberculosis (MTB). This proposal aims to transform MTB vaccine formulations by combining cutting-edge mRNA technologies and advanced adaptive immune receptor sequencing. This bolsters the EU’s leadership in vaccine R&D, specifically: refinement and validation of novel mRNA MTB vaccines. This proposal comprises WP5.5, focused on non-human primates, and WP6.3, focused on a human clinical trial. WP5.5 will apply OS’s proprietary OS-T sequencing platform for in-depth single-cell T cell receptor (TCR) sequencing, providing unprecedented data granularity and permitting exhaustive characterization of adaptive immune responses. Integrated advanced statistical and machine learning models will quantify the protective efficacy of xeno-epitope-encoded mRNA vaccine candidates. WP6.3 will validate patients’ cellular responses in the accompanying Phase I clinical trial by assaying dynamic TCR sequences to quantify correlates of protection and immunogenicity in humans. OS brings substantial, unique expertise in adaptive immune receptor sequencing and analysis. The company’s data management allows it to navigate the complexities of large-scale genomic data, ensuring robust, reproducible and open scientific findings. Research outcomes will serve multiple layers of scientific and societal impact. Effective vaccine formulations will be refined and validated, offering immediate benefits in combating MTB as a major goal of BAXERNA 2.0. Eventually, the in-depth TCR sequencing and accompanying analyses will provide new insight into fundamental responses of the human body to mRNA vaccines targeting intracellular bacteria. This will generate a robust data infrastructure and methodological framework for evaluating vaccine response, adaptable for other pathogens, extending utility beyond the immediate scope of this project

Keywords: biotech,sme,immune response,high definition,tuberculosis,buruli ulcer,acinetobacter baumannii,mass spectrometry,proteomics,bioinformatics,mrna vaccine,adjuvants,immunity
Solid-State Cooling Technology for Cryogenic Devices (SoCool)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Transition
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Finland
Call: EIC Transition Open 2022 (HORIZON-EIC-2022-TRANSITION-01, 2022)
Start date: 2023-06-01
End date: 2026-05-31
Duration (months): 36.0
Total project cost (EUR): 1298411.0
EU funding (EUR): 1298411.0
Participants: 1
Project status: SIGNED

Temperatures below 1 kelvin are highly beneficial, if not prerequisite, to several important technologies that are key to development in present and upcoming decades. Examples include superconducting electronics such as x-ray calorimeters, qubits, single-photon detectors and RF amplifiers. In spite of the typically small size of the elements to be refrigerated, the techniques commonly used to access sub-kelvin temperatures are expensive and cumbersome, due to intrinsic need of circulating the rare 3He cryogen or the heavy magnets required for their refrigeration. These limitations have been an obstacle to broad-scale deployment of sub-kelvin electronics and photonics. Here we develop an extremely compact and fully electrical general purpose solid-state refrigerator, able to continuously cool electronic and photonic devices from above 1 K to below 100 mK, without any need of thermodynamic cycles based on 3He cryogenic fluid or magnetic fields. Our approach is based on a recent technological discovery which showed that superconductive tunnel junctions can in fact operate similarly as vacuum isolated thermionic coolers. This approach provides full scalability for the total cooling power and ability to create large temperature drops with cryogenic electrical coolers - features not available before. We follow this approach and engineer a 3D stacked multi-chip cooler system. We capitalize on several of our previous milestones and aim to demonstrate a complete cooler system that can reach performance comparable with dilution refrigeration, without need of 3He and at a fraction of the mass and cost. Our vision entails new application avenues in the fields of quantum technology, material analysis and surveying, radiation detection, cosmology, and astronomy. We expect significant impact for airborne or space-oriented applications, because of the breakthrough reduction in payload mass and complexity allowed by our cooling solution.

Keywords: cryogenics,sensors,quantum technologies,quantum computing,refrigeration,high performance microsystems,microelectronics,superconductivity,integrated circuits